Infectious Diseases
Feature
As COVID treatments dwindle, are new ones waiting in the wings?
Bebtelovimab couldn’t neutralize the Omicron subvariants BQ.1 and BQ.1.1.
From the Journals
Multidrug-resistant gram-negative infections treatable with newer antibiotics, but guidance is needed
They found that these infections were the second leading cause of death worldwide.
Feature
Rise of the fungi: Pandemic tied to increasing fungal infections
COVID-19 has lifted the lid on the risks of secondary pulmonary fungal infections.
Feature
Paxlovid has been free so far. Next year, sticker shock awaits
The Pfizer pill has helped prevent many people infected with COVID-19 from being hospitalized or dying,
News from the FDA/CDC
Children and COVID: Hospitalizations provide a tale of two sources
Thanksgiving travel seems to have had little effect on new pediatric cases.
News
Study comparing surgical and N95 masks sparks concern
The findings are not consistent with those of many other studies on this topic.
Feature
Pediatric emergencies associated with unnecessary testing: AAP
Several common pediatric conditions do not require diagnostic tests.
News
FDA pulls U.S. authorization for Eli Lilly’s COVID drug bebtelovimab
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Feature
RSV surge stuns parents and strains providers, but doctors offer help
The parents of the child who had a severe case of RSV reflected on the their son’s bout with the illness.
Feature
Covid vax prevents death in children regardless of variant
But the vaccine’s effectiveness decreased over time.
Conference Coverage
Newer agents for nosocomial pneumonia: The right drug for the right bug
“The right drug at the right time with the right dose for the right bug for the right duration.”